FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann
NEW YORK (Reuters) – Novartis (NOVN.S) said on Wednesday that the chief science officer and top research and development executive at its Avexis unit are no longer at the company after some data from early testing of the unit’s more than $2 million gene therapy Zolgensma was manipulated.
Novartis said in a statement that Avexis Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019.
It said it named Page Bouchard as Avexis’ senior vice president of research and chief scientific officer, effective Aug. 5.
Reporting by Michael Erman, Editing by Franklin Paul